🚀 10 Upcoming PDUFAs in December! ❄️

Buckle up! See FDA PDUFA update 👇
$Ionis Pharmaceuticals (IONS.US)$ ⇨ IONIS-APOCIII-LRx (Olezarsen)
$ZLDPF ⇨ Glepaglutide
$Rhythm Pharmaceuticals (RYTM.US)$ ⇨ IMCIVREE™ (Setmelanotide)
$Mirum Pharmaceuticals (MIRM.US)$ ⇨ Chenodal® (chenodiol)
$Checkpoint Therapeutics (CKPT.US)$ ⇨ Cosibelimab (CK-301)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinecerfont capsule
$Bristol-Myers Squibb (BMY.US)$ ⇨ Opdivo® Subcutaneous (nivolumab + hyaluronidase)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinecerfont oral solution
$BeiGene (BGNE.US)$ ⇨ Tislelizumab + chemo
$AstraZeneca (AZN.US)$ ⇨ Dato-DXd (Datopotamab deruxtecan)

🗓️ Last Week’s PDUFA decisions:
$AstraZeneca (AZN.US)$ : Approved 12/5/24 ✅
⇨ Imfinzi (durvalumab)
‣ Limited-stage small cell lung cancer
‣ PDUFA: Q4 2024 (sBLA)

$Merus (MRUS.US)$ : Approved 12/4/24 ✅
⇨ BIZENGRI® (zenocutuzumab-zbco)
‣ NRG1+ pancreatic adenocarcinoma & NSCLC
‣ PDUFA: 2/4/25 (BLA)